Pressrooom

 

Medscape Medical News: FDA Panels Say Risks of Opana ER Outweigh Benefits

A panel of US Food and Drug Administration (FDA) experts has advised the agency that the risks of an abuse-deterrent extended-release formulation of oxymorphone (Opana ER, Endo Pharmaceuticals) for relief of severe pain now outweigh its benefits. Read here.

Julie Livingston

Contact: Julie@medshadow.org / 347-239-0249

Average: 0

 

Last updated: March 27, 2017